"Phathom's sole commercial asset, VOQUEZNA, is a potassium-competitive acid blocker approved for GERD and H. pylori treatment. Prescription momentum has been consistent, with quarterly fills growing from ~127,000 in Q1 2025 to ~273,000 in Q4 2025, pushing cumulative totals past 1.1 million prescriptions."
"Management has guided for $320-$345 million in FY 2026 net revenue and expects to reach operating profitability beginning in Q3 2026. Barclays' $18 target remains below the broader analyst consensus target of $23.50."
Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals to Overweight from Equal Weight, increasing the price target to $18. The stock is currently trading at $10.69, down nearly 32% year-to-date despite strong fundamentals. Barclays anticipates a significant volume and revenue ramp for the remainder of 2026. Prescription trends are lighter, but the firm sees potential catalysts in weekly prescription data. Phathom's revenue for Q4 was $57.58 million, up 94.12% year-over-year, and management expects to reach operating profitability in Q3 2026.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]